Navigation Links
Pulmonx Announces New President and CEO Michael A. Baker to Lead Interventional Pulmonology Company
Date:7/15/2009

REDWOOD CITY, Calif., July 15 /PRNewswire/ -- Pulmonx, an emerging leader in interventional pulmonology and in the development of device therapies for the treatment of emphysema announced today that Michael A. Baker has joined the company as President and CEO and that he has been elected as a member of its board of directors.

"We are very excited that Mike will be leading our company as we begin to commercialize our proprietary medical device therapies for these important indications," said Dr. Rodney Perkins, Founder and Chairman of the Board. "The strategic and leadership skills he has developed over the course of his career will be of great value to Pulmonx."

Mr. Baker's professional career comprises over two decades of executive experience in the medical device industry with much of it directly focused on the development and commercialization of new device technologies and device-based therapies. His career includes assignments with ArthroCare Corporation, where he served as the President and CEO for over 11 years, and with Medtronic, where he served for over 8 years in executive and general management assignments in both the United States and Europe. Mr. Baker holds an M.B.A. from the University of Chicago and a B.S. from the United States Military Academy at West Point.

The addition of Mike Baker follows a series of strategic developments including the receipt of FDA marketing clearance for a key new product and the completion of a successful acquisition. In early July, the company received FDA marketing clearance for the Chartis System, an assessment tool which allows physicians to make regional assessments of lung function, including quantifying inter-lobar airflow in the lungs, known as collateral ventilation. Recent research suggests that the presence of collateral ventilation may have an important impact on the effectiveness of Endobronchial Lung Volume Reduction (ELVR) therapy(1, 2). By helping physicians to identify the presence of collateral ventilation, the Chartis System may enable them to better identify patients who could benefit from endobronchial valve therapy.

The FDA clearance follows Pulmonx's recent acquisition of Emphasys Medical, which added Emphasys' Zephyr family of endobronchial valves for ELVR to the company's proprietary portfolio of diagnostic and therapeutic products. The Zephyr endobronchial valves are already CE marked and commercially available in many countries around the world. Pulmonx intends to begin international commercialization of the Chartis system as soon as it receives the CE mark.

"This is an exciting time for all of us here at Pulmonx," commented Mike Baker, President and CEO of Pulmonx. "With the completion of the acquisition of Emphasys Medical, Inc. and 510K clearance of our Chartis System, Pulmonx is poised to become a leader in the treatment of pulmonary disorders such as severe emphysema. These new technologies have the potential to cost-effectively improve the health of literally millions of patients globally and I'm extremely enthusiastic about the opportunity to lead this outstanding team as we work to commercialize these breakthrough products and build a strong franchise in Interventional Pulmonology."

About Pulmonx

Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. Pulmonx is venture funded by Montreux Ventures, MedVenture Associates, DeNovo Ventures, Latterell Ventures, Covidien Ventures and Posco Bioventures.

(1) Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.

(2) Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.


'/>"/>
SOURCE Pulmonx Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting
2. VA Announces $26 Million Construction Contract for Palo Alto
3. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results
4. CorVel Announces Earnings Release Webcast
5. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures
6. Wonderbox Technologies(R) Announces 2nd Annual Super User of the Year
7. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
8. Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship
9. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
10. Snoring Isn't Sexy, LLC Announces Professional Relationship with the American Sleep Apnea Association
11. Management Health Solutions, Inc. Announces Optimal Inventory Control™ (OptIC™) Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... New York (PRWEB) , ... June 24, 2016 , ... ... marijuana patients optimize the ingestion of their medication by matching users with high quality ... users to compare pieces with no commitment. , Inhale was founded by two brothers, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: